Lung Cancer in Estonia.

Autor: Laisaar T; Lung Clinic, Tartu University Hospital, Tartu, Estonia; Lung Clinic, Institute of Clinical Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia; Institute of Family Medicine and Public Health, Faculty of Medicine, University of Tartu, Tartu, Estonia. Electronic address: tanel.laisaar@kliinikum.ee., Innos K; National Institute for Health Development, Tallinn, Estonia., Jaal J; Haematology and Oncology Clinic, Tartu University Hospital, Tartu, Estonia; Haematology and Oncology Clinic, Institute of Clinical Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia., Oselin K; Clinic of Oncology and Hematology, North Estonia Medical Center, Tallinn, Estonia., Sarana B; Lung Clinic, Tartu University Hospital, Tartu, Estonia., Vanakesa T; Thoracic Surgery Department, Cardiothoracic Surgery Center, North Estonia Medical Center, Tallinn, Estonia., Laisaar KT; Institute of Family Medicine and Public Health, Faculty of Medicine, University of Tartu, Tartu, Estonia.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Aug; Vol. 19 (8), pp. 1138-1145.

Inhibition of epigenetic and cell cycle-related targets in glioblastoma cell lines reveals that onametostat reduces proliferation and viability in both normoxic and hypoxic conditions.

Autor: Lavogina D; Institute of Clinical Medicine, University of Tartu, L. Puusepa 8, 50406, Tartu, Estonia. darja.lavogina@ut.ee.; Chair of Bioorganic Chemistry, Institute of Chemistry, University of Tartu, Tartu, Estonia. darja.lavogina@ut.ee.; Competence Centre on Health Technologies, Tartu, Estonia. darja.lavogina@ut.ee., Krõlov MK; Chair of Bioorganic Chemistry, Institute of Chemistry, University of Tartu, Tartu, Estonia., Vellama H; Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.; Centre of Excellence for Genomics and Translational Medicine, University of Tartu, Tartu, Estonia., Modhukur V; Competence Centre on Health Technologies, Tartu, Estonia.; Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia., Di Nisio V; Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Huddinge, Stockholm, Sweden.; Division of Obstetrics and Gynecology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Huddinge, Stockholm, Sweden., Lust H; Institute of Clinical Medicine, University of Tartu, L. Puusepa 8, 50406, Tartu, Estonia., Eskla KL; Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.; Centre of Excellence for Genomics and Translational Medicine, University of Tartu, Tartu, Estonia., Salumets A; Competence Centre on Health Technologies, Tartu, Estonia.; Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.; Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Huddinge, Stockholm, Sweden.; Division of Obstetrics and Gynecology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Huddinge, Stockholm, Sweden., Jaal J; Institute of Clinical Medicine, University of Tartu, L. Puusepa 8, 50406, Tartu, Estonia. jana.jaal@ut.ee.; Department of Radiotherapy and Oncological Therapy, Tartu University Hospital, Tartu, Estonia. jana.jaal@ut.ee.

Publikováno v: Scientific reports [Sci Rep] 2024 Feb 21; Vol. 14 (1), pp. 4303. Date of Electronic Publication: 2024 Feb 21.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Exploring the Molecular Players behind the Potentiation of Chemotherapy Effects by Durvalumab in Lung Adenocarcinoma Cell Lines.

Autor: Saar M; Institute of Clinical Medicine, Faculty of Medicine, University of Tartu, 50406 Tartu, Estonia.; Institute of Pharmacy, University of Tartu, 50411 Tartu, Estonia.; Pharmacy, Tartu University Hospital, 50406 Tartu, Estonia., Jaal J; Institute of Clinical Medicine, Faculty of Medicine, University of Tartu, 50406 Tartu, Estonia.; Haematology and Oncology Clinic, Tartu University Hospital, 50406 Tartu, Estonia., Meltsov A; Competence Centre on Health Technologies, 50411 Tartu, Estonia.; Department of Genetics and Cell Biology, GROW School for Oncology and Developmental Biology, Maastricht University, 6200 MD Maastricht, The Netherlands., Laasfeld T; Institute of Chemistry, University of Tartu, 50411 Tartu, Estonia.; Department of Computer Science, University of Tartu, 51009 Tartu, Estonia., Lust H; Institute of Clinical Medicine, Faculty of Medicine, University of Tartu, 50406 Tartu, Estonia., Kasvandik S; Proteomics Core Facility, Institute of Technology, University of Tartu, 50411 Tartu, Estonia., Lavogina D; Institute of Clinical Medicine, Faculty of Medicine, University of Tartu, 50406 Tartu, Estonia.; Competence Centre on Health Technologies, 50411 Tartu, Estonia.; Institute of Chemistry, University of Tartu, 50411 Tartu, Estonia.

Publikováno v: Pharmaceutics [Pharmaceutics] 2023 May 12; Vol. 15 (5). Date of Electronic Publication: 2023 May 12.

Conjugates of adenosine mimetics and arginine-rich peptides serve as inhibitors and fluorescent probes but not as long-lifetime photoluminescent probes for protein arginine methyltransferases.

Autor: Lavogina D; Institute of Chemistry, University of Tartu, Tartu, Estonia.; Institute of Clinical Medicine, University of Tartu, Tartu, Estonia., Nasirova N; Institute of Chemistry, University of Tartu, Tartu, Estonia., Sõrmus T; Institute of Chemistry, University of Tartu, Tartu, Estonia., Tähtjärv T; Institute of Chemistry, University of Tartu, Tartu, Estonia., Enkvist E; Institute of Chemistry, University of Tartu, Tartu, Estonia., Viht K; Institute of Chemistry, University of Tartu, Tartu, Estonia., Haljasorg T; Institute of Chemistry, University of Tartu, Tartu, Estonia., Herodes K; Institute of Chemistry, University of Tartu, Tartu, Estonia., Jaal J; Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.; Department of Radiotherapy and Oncological Therapy, Tartu University Hospital, Tartu, Estonia., Uri A; Institute of Chemistry, University of Tartu, Tartu, Estonia.

Publikováno v: Journal of peptide science : an official publication of the European Peptide Society [J Pept Sci] 2023 Mar; Vol. 29 (3), pp. e3456. Date of Electronic Publication: 2022 Oct 28.